MedTrace Logo

Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer

NCT00336934 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2011-08-15

No results posted yet for this study

Summary

RATIONALE: Pomegranate extract may keep prostate cancer from growing in patients with rising prostate-specific antigen (PSA) levels after surgery or radiation therapy for localized prostate cancer.

PURPOSE: This randomized trial is studying how well pomegranate extract works in treating patients with rising PSA levels after surgery or radiation therapy for localized prostate cancer.

Conditions

Interventions

DIETARY_SUPPLEMENT

pomegranate juice

Given orally daily.

OTHER

placebo

Given orally daily.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Roll International Corporation

    lead INDUSTRY

Principal Investigators

  • Allan Pantuck, MD · Jonsson Comprehensive Cancer Center

  • Arie Belldegrun, MD, FACS · Jonsson Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2010-07-31
Completion
2010-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00336934 on ClinicalTrials.gov